Dr Jennifer Bryant BSC, PhD

Dr Jennifer Bryant

Institute of Cancer and Genomic Sciences
Research Fellow

Contact details

Institute of Head and Neck Studies and Education (InHANSE)
Institute of Cancer and Genomic Sciences
2nd Floor, Robert Aitken Building
University of Birmingham
Birmingham B15 2TT

I am a post-doctoral researcher within InHANSE where we oversee sample collection from a number of clinical trials and carry out pre-clinical evaluation of drugs. I am currently investigating a number of repurposed drugs and novel therapeutics in order to assess their potential for treating head and neck cancer as well as gain information about their mechanisms of action.


  • PhD in Molecular Cancer Studies, University of Manchester 2015
  • BSc (Hons) Biology with Professional Placement, University of Bath 2011


I received my BSc in Biology from the University of Bath in 2011. During my degree, I undertook a 12 month placement at the University of Kentucky in the laboratory of Professor Penni Black. My PhD was completed between 2011 and 2015 under the supervision of Professor Anne White and Professor Kaye Williams at the University of Manchester. Here I investigated small cell lung cancer and novel, hypoxia-targeted therapy. Following a 6 month post-doc in the laboratory of Dr Harmesh Aojula, University of Manchester, I joined the InHANSE team at the University of Birmingham in Professor Hisham Mehanna’s research team. Here, I have been investigating therapies for head and neck cancer. I am particularly interested in advancing research from the bench into the clinic as efficiently and safely as possible, as well as understanding the mechanism behind drug response.


  • BMedSci: Introduction to Genetics
  • BMedSci: Stem Cell practical sessions


Pre-clinical investigation of novel and repurposed drugs to treat head and neck cancer. Using the AcceleraTED platform, our group aims to reduce the time taken for drugs to reach the clinic. We carry out high throughput screening and mechanistic studies on drugs and novel compounds as well as in vivo evaluation of toxicity and efficacy before proceeding into clinical trials.

InHANSE - @InHANSEresearch (Twitter)



Offerman S, Kadirvel M, Abusura O, Bryant JL, Telfer BA, Brown G, Freeman S, White A, Williams KJ, Aojula HS. (2016).       N-tert-Prenylation of indole ring improves the cytotoxicity of a short antagonist G analogue against Small Cell Lung Cancer. Med. Chem. Commun, 8, 551-558

Meredith SL, Bryant JL, Babur M, Roddell P, Behrouzi R, Williams KJ, White A. (2016). Irradiation Decreases the Neuroendocrine Biomarker Pro-Opiomelanocortin in Small Cell Lung Cancer Cells In Vitro and In Vivo. PLoS One 11(2): e0148404

Bryant JL, Meredith SL, Williams KW, White A. (2014). Targeting hypoxia in small cell lung cancer. Lung Cancer 86(2), 126-132

Stovold R, Meredith SL, Bryant JL, Babur M, Williams KJ, Dean EJ, Dive C, Blackhall FH, White A (2013). Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients. Br J Cancer 108(8): 1704-11

Bryant JL, Britson J, Balko JM, Willian M, Timmons R, Frolov A, Black EP (2012). A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br J Cancer 106:148–156


View all publications in research portal